Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

10.63USD
3:39pm EST
Change (% chg)

$0.02 (+0.19%)
Prev Close
$10.61
Open
$10.60
Day's High
$10.86
Day's Low
$10.59
Volume
16,183
Avg. Vol
61,853
52-wk High
$11.40
52-wk Low
$4.40

Select another date:

Wed, Feb 7 2018

BRIEF-MediciNova Announces Proposed Underwritten Public Offering

* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)

* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

BRIEF-Medicinova announces collaboration

* Medicinova announces collaboration with the U.S. Department Of Veterans Affairs and Oregon Health & Science University to evaluate MN-166 (ibudilast) in methamphetamine use disorder

BRIEF-Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)

* Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability

BRIEF-Medicinova Inc files for potential mixed ‍​shelf of up to $200 million

* Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing Source text: [http://bit.ly/2fgDO2R] Further company coverage:

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

Select another date: